BioMarin Pharmaceuticals Inc (BMRN)
What changed this quarter
- Risk factors — 9 added · 4 removed · new: We have in the past and may in the future p… +8
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Company overview
BioMarin. A biotech specialized in drugs for rare enzyme-deficiency diseases. It generates stable income via high drug prices and few competitors.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
BioMarin Pharmaceuticals Inc is classified under the Biotech & Health sector. See peers below.
BioMarin Pharmaceuticals Inc key financials
Based on SEC filings · latest quarter (TTM)
Tap a metric name to see its meaning in the glossary.
BMRN on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — valuation and growth vs the Biotech & Health average
Peers · Biotech & Health
BMRN FAQ
What is BioMarin Pharmaceuticals Inc (BMRN)?
BioMarin. A biotech specialized in drugs for rare enzyme-deficiency diseases. It generates stable income via high drug prices and few competitors.
What sector is BioMarin Pharmaceuticals Inc in?
BioMarin Pharmaceuticals Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are BioMarin Pharmaceuticals Inc's key financials?
Based on the latest quarter (TTM) from SEC filings: Revenue growth (YoY) 9.9%, Operating margin 16.9%, Net margin 8.3%, ROE 5.7%. Definitions and interpretation are available on Stocklore.
Where can I analyze BioMarin Pharmaceuticals Inc (BMRN) stock?
On Stocklore you can see BMRN's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.